Dovato (dolutegravir/lamivudine) – Expanded indication
April 8, 2024 - ViiV Healthcare announced the FDA approval of Dovato (dolutegravir/ lamivudine), as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of Dovato.
Top